On September 6–7, 2025, the “GoBroad Medical Forum – The 5th Shanghai Clinical Application Symposium and Training Course on Autologous Hematopoietic Stem Cell Transplantation (ASCT)” was successfully held in Shanghai. The event was organized by GHG Shanghai Zhaxin Hospital and Shanghai Liqian Hospital.

This year's symposium and training program not only featured a comprehensive main transplantation forum with a strong emphasis on practical application, but also established dedicated sub-forums on multiple myeloma, lymphoma, ASCT combined with CAR-T therapy, plasma cell immunotherapy, and nursing. Nearly 100 renowned experts from across the country—including leading figures in hematopoietic stem cell transplantation and distinguished scholars in hematologic oncology—delivered lectures on-site, sharing valuable clinical experience, research outcomes, and cutting-edge perspectives. Nearly 200 hematologists and nurses gathered to engage in in-depth, multidimensional discussions on the latest advances in transplantation techniques and clinical challenges.

“Distinctive, High-Level, Staying True to Our Mission”

At the opening ceremony, Professor Wang Chun, Executive Chairman of the conference and Medical Director of GHG Shanghai Zhaxin/Liqian Hospitals, delivered the keynote address. He reviewed the development of the two hospital campuses and emphasized that since their establishment, his team has remained patient-centered, continuously innovating and breaking new ground to forge a distinctive diagnostic and treatment approach—becoming the last line of defense for hematologic diseases in Shanghai. Over the past five years, the two campuses have completed more than 800 transplants. Beyond this quantitative milestone, the team has tackled some of the toughest challenges in hematologic oncology, including:

1. Performing life-saving transplants for refractory patients who failed to achieve remission, enabling significant survival benefits for many;
2. Successfully conducting transplants in elderly patients, with 24% aged over 60 and the oldest at 74;
3. Advancing transplantation in difficult cases such as myelofibrosis, refractory peripheral T-cell lymphoma, and highly DSA-positive patients;
4. Establishing a cell immunotherapy platform in collaboration with Beijing GoBroad Hospital, offering diverse treatment options for complex, relapsed, and refractory hematologic malignancies, including pioneering ASCT combined with CAR-T therapy with breakthrough results;
5. Developing strong anti-infection capabilities to address the critical challenge of infection in hematologic patients, delivering individualized, rapid, and precise treatment;
6. Introducing an integrated model of Traditional Chinese Medicine (TCM) and Western medicine in post-transplant supportive care, creating a distinctive system for managing complications such as infections, rejection, and severe frailty.

Five Sub-Forums Highlight Breakthroughs in Hematology

The five thematic sub-forums were rich in content and academic highlights.

• Multiple Myeloma Forum: Focused on three key clinical questions—patient selection for transplantation, the role of high-dose melphalan, and transplant feasibility in renal impairment—combining theoretical insights with case discussions to promote standardized practice.
• Lymphoma Forum: Addressed ASCT strategies for high-risk and relapsed/refractory patients, with special focus on central nervous system lymphoma.
• CAR-T Forum: Emphasized the innovative integration of transplantation and cellular immunotherapy, showcasing remarkable clinical efficacy in NHL and MM through case demonstrations.
• Plasma Cell Immunotherapy Forum: Interpreted the latest findings from the 2025 EHA Congress, with in-depth discussions on bispecific antibodies, CAR-T applications, and clinical sequencing strategies.
• Nursing Forum: Highlighted full-cycle nursing management in transplantation and immunotherapy, underscoring the professional and humanistic advances achieved by the GHG nursing team.

With a strong academic atmosphere, these sub-forums fostered close interaction between experts, clinicians, and nurses, driving progress in hematology from basic research to clinical practice and from treatment strategies to nursing management—injecting new momentum into the standardized and precise development of hematology in China.

Conclusion

Since their founding, GHG Shanghai Zhaxin and Liqian Hospitals have maintained close and extensive academic exchanges with hematology experts in Shanghai and nationwide. To date, related academic activities have engaged over 900 physicians, with nearly 3,000 total participations, covering more than 400 hospitals across China. These initiatives have created a vibrant platform for learning and dialogue on transplantation, fueling robust academic influence and contributing to the advancement of hematology in China.